Pharmaceuticals

Gastrointestinal Therapeutics Sector Forecast Shows Robust Momentum, Climbing to $55.21 Billion With 5.4% CAGR

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gastrointestinal therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Gastrointestinal Therapeutics Market from 2026 to 2030?

The gastrointestinal therapeutics market size has experienced robust growth in recent years. It is anticipated to increase from $42.3 billion in 2025 to $44.72 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. The expansion witnessed in the past can be attributed to several factors, including the constrained availability of biologics and sophisticated gastrointestinal treatments, a rising prevalence of acid reflux and ulcers, a reliance on hospital and clinic-based treatment modalities, increasing public awareness of digestive health, and the significant role of traditional over-the-counter antacids and laxatives.

The gastrointestinal therapeutics market size is anticipated to experience substantial growth in the coming years, expanding to $55.21 billion by 2030 with a compound annual growth rate (CAGR) of 5.4%. This projected growth can be attributed to factors such as the development of targeted biologics and immunotherapies, the expansion of ambulatory surgical centers and diagnostic laboratories, the increasing adoption of oral and intravenous delivery systems, a rising penetration of online pharmacies, and innovations in probiotic and digestive enzyme formulations. Major trends for this period include the escalating prevalence of gastrointestinal disorders, a greater uptake of biologics and advanced therapies, the widening availability of over-the-counter therapeutics, a growing emphasis on personalized gastrointestinal treatments, and the increasing distribution through online and retail pharmacies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

What Drivers Are Affecting Demand In The Gastrointestinal Therapeutics Market?

The increasing prevalence of inflammatory bowel diseases is projected to fuel the expansion of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a chronic disorder that causes inflammation of the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases stems from genetic susceptibility, which triggers an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating these bowel conditions by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, the IBD Registry, a UK-based non-profit organization, reported that over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, indicating an increase of more than 3,000 members from 2022. Consequently, the rising inflammatory bowel diseases are driving the growth of the gastrointestinal therapeutics market.

Which Segment Groups Are Influencing The Gastrointestinal Therapeutics Market?

The gastrointestinal therapeutics market covered in this report is segmented –

1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

Which Trends Are Influencing The Performance And Direction Of The Gastrointestinal Therapeutics Market?

Companies operating in the gastrointestinal therapeutics market are concentrating on developing innovative treatments, such as sustained-release (SR) fixed-dose combination capsules, to improve patient compliance and enhance treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, maintaining consistent drug levels and reducing dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, launched rabeprazole + levosulpiride SR capsules for treating gastrointestinal disorders in India. This formulation combines rabeprazole, a proton pump inhibitor that decreases stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, they offer effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is widely prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.

Who Are The Major Companies Operating In The Gastrointestinal Therapeutics Market?

Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Gastrointestinal Therapeutics Market?

North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastrointestinal Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25768&type=smp

Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Digestive And Intestinal Remedies Market Report 2026

https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795